Navigation Links
New "second-line" AIDS Drug Shows Promise in Trials

An experimental drug that researchers hope will cast a lifeline to HIV patients who have exhausted first-line treatment has shown early promise in long-awaited trials, The Lancet reports on Saturday.

Etravirine, also called TMC125, is designed as an alternative for patients who are resistant to a class of drugs called non-nucleoside reverse transcriptase inhibitors (NNRTIs).

An international consortium of doctors has been testing etravirine on NNRTI-resistant patients in two 48-week trials, the third and final phase of a long and complex process to assess new drugs for safety and effectiveness.

The volunteers in the DUET 1 and 2 trials are divided into two groups. Half receive etravrine and half a dummy, lookalike pill, a placebo.

In addition, all receive two standard anti-HIV drugs from a different treatment class, known as protease inhibitors, and also take selected NNRTIs.

The benchmark of success for helping patients with resistance problems is a "viral load" -- a count of the human immunodeficiency virus (HIV) which causes AIDS) -- to below 50 viruses per millilitre of blood.

At the 24-week point in the two trials, 56 and 62 percent of patients in the etravirine group had achieved this goal, The Lancet paper says. Among the "placebo" group, the rate was 39 and 44 percent.

Side effects were "mild or moderate" in severity, with generally little difference between the etravirine-takers and the placebo group.

Etravirine, made by a Belgian firm, Tibotec, has been closely followed by AIDS campaigners.

Antiretroviral drugs, as drugs to combat HIV are known, can save people with the AIDS virus, although they are not a cure.

But the longer a patient receives these drugs, the likelier it is that he or she will develop resistance problems as the virus mutates. In the case of NNRTIs, HIV can sidestep existing drugs with just a tiny mu tation in a single amino acid.

The treatment options narrow further if a patient is found to suffer bad side effects from these powerful molecules.

The hope for etravirine is that it will open up a new front against resistant virus and raise the genetic barrier to developing resistance.


'"/>




Related medicine news :

1. Experimental treatment for Ebola Virus Shows promising results in mice
2. New Prostate Cancer Vaccine Shows Promise
3. Ebola Treatment Shows Promise
4. New Drug Shows Significant Improvement In HIV-related Heart Condition
5. Greek Study Shows Living In The Hills May Be Healthier
6. Research Shows Carbon Monoxide Prevents Inflammations
7. Latest Research Shows That Multivitamins Might Not Prevent Infections In All Elderly
8. Novartis MS Drug Shows Promising Results
9. MRI Shows Emotional Changes During Menstrual Cycle
10. Bronchiolo-alveolar Carcinoma Shows Sonographic Pattern Of Pneumonia
11. AIDS drug GS 9137 Shows Promise
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/27/2017)... ... March 27, 2017 , ... The Association of Healthcare and ... hold their first Northeast Regional AHVAP Meeting. For 2017, Dr. Hayes will provide ... and value analysis professionals have a ‘seat at the table’ with clinical committees ...
(Date:3/27/2017)... , ... March 27, 2017 , ... According to the ... cancer, including all stages, is more than 95%. Once the cancer spreads to other ... than 30%. To find out how to avoid this latter group, tune in to ...
(Date:3/27/2017)... ... March 27, 2017 , ... Sodium ... methods are complicated and require expert user knowledge. In a live webinar on ... to the simplified, yet highly accurate, determination of sodium. , It has long ...
(Date:3/27/2017)... ... March 27, 2017 , ... ?Grow Healthy Vending LLC announced ... litigation between itself and 1800 Vending DBA Healthy You Vending. (Civil No. 1:14-CV-00121-CW/ ... to announce that we have now reached a settlement agreement regarding the ongoing ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... deaths soared 167%,(1) with opioids alone responsible for over 33,000 of the 52,404 ... has sponsored Assembly Bill (AB) 1512, which proposes a tax on prescription opioids ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... --  Genprex, Inc. , a privately held, clinical-stage biopharmaceutical company developing ... Company,s Chief Operating Officer, is scheduled to present a corporate overview ... Annual Cancer BioPartnering & Investment Forum: Tuesday, March 28, 2017 at ... ... Annual Future Leaders in Biotech Industry – Friday, April 7, 2017 ...
(Date:3/27/2017)... -- Invivotek, LLC, a Genesis Biotechnology Group ® ... contract research organization (CRO), announced the completion of the ... research facility in Hamilton, New Jersey ... source to reduce costs and lessen the CRO facility,s ... Farm follows Invivotek,s recent expansion from a 19,712 square ...
(Date:3/24/2017)... Oregon and PUNE, India , March 24, 2017 /PRNewswire/ ... 2015, and is estimated to reach $2,614 million by 2022, Globally, registering a CAGR ... to generate the highest revenue, and is projected to dominate the market during the ... ... Allied Market Research Logo ...
Breaking Medicine Technology: